Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company focused on developing innovative therapies for life-threatening diseases. This page provides investors and healthcare professionals with timely updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of Gilead's press releases and news, including updates on antiviral therapies, oncology research, and clinical trial results. Our curated collection features earnings announcements, partnership details, and progress reports on treatments for HIV, hepatitis, and emerging cancer therapies.
Stay informed about critical developments through verified updates on FDA approvals, research collaborations, and therapeutic advancements. All content is organized chronologically for quick reference, with clear sourcing to ensure transparency.
Bookmark this page for streamlined access to Gilead Sciences' official communications and third-party analysis. Regularly updated to reflect the company's evolving pipeline and market position, this resource supports informed decision-making for stakeholders at all levels.
Gilead Sciences (NASDAQ: GILD) announced an $85 million contribution to the
Gilead Sciences announced a new joint procurement agreement (JPA) with the European Commission to ensure equitable access to Veklury (remdesivir) for COVID-19 patients across the EU and EEA. This agreement, effective for 12 months with a possible 6-month extension, follows the expiration of the original JPA. Veklury is crucial as it is the only antiviral licensed in this region for treating COVID-19 patients requiring supplemental oxygen. Positive results from clinical trials have increased its indications, reinforcing its role as a key treatment in combating COVID-19.
Gilead Sciences (Nasdaq: GILD) will release its Q2 2022 financial results on August 2, after market close. A webcast discussing the results will be held at 4:30 p.m. Eastern Time that same day. Gilead is a biopharmaceutical company focused on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer. With over three decades of breakthroughs, Gilead operates in more than 35 countries, headquartered in Foster City, California.
Gilead Sciences (GILD) announced the retirement of Brett Pletcher, Executive Vice President, Corporate Affairs, after 17 years. Deborah Telman will succeed him as Executive Vice President and General Counsel, effective August 1, 2022. Telman, who joins from Organon, brings over 25 years of legal experience and will oversee legal and corporate affairs. CEO Daniel O'Day praised Telman's leadership and commitment to health equity. Pletcher's tenure included significant contributions to Gilead's global expansion and health policy strategy.
Kite, a Gilead Company (Nasdaq: GILD), announces European Commission approval for Yescarta (axicabtagene ciloleucel) to treat adults with relapsed or refractory follicular lymphoma after three or more lines of therapy. The pivotal ZUMA-5 study demonstrated a 91% overall response rate and a 77% complete response rate among patients treated. Follicular lymphoma, the second most common lymphoma type, has limited treatment options, making this approval significant. Kite aims to improve access to innovative cancer therapies across Europe.
Gilead Sciences has resubmitted the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 treatment for heavily treatment-experienced patients with multi-drug resistant infections. This follows the FDA's Complete Response Letter issued in February 2022 concerning vial compatibility issues. The resubmission includes comprehensive data on compatibility with a new vial type. If approved, lenacapavir would be the only HIV-1 treatment option administered biannually. The FDA will establish a new PDUFA date upon acceptance of this NDA.
Gilead Sciences has signed the Kigali Declaration to combat neglected tropical diseases (NTDs) by 2030, reinforcing its commitment to global health. This declaration, launched during the Commonwealth Heads of Government Meeting, aims to eliminate 20 diseases by 2030. Gilead's CEO, Daniel O'Day, emphasized the company's long history of supporting NTD efforts. Gilead will continue its product donations for visceral leishmaniasis until 2027, invest in health equity initiatives, and lead discussions on environmental factors contributing to NTDs.
Gilead Sciences announced that the European Medicines Agency's CHMP has issued a positive opinion for lenacapavir, an investigational treatment for HIV-1 infection in adults with multi-drug resistance. This recommendation, based on Week 26 data from the CAPELLA trial, supports lenacapavir as a twice-yearly treatment option for patients with limited options. In the trial, 81% of participants achieved viral suppression, with lenacapavir showing good tolerability. The final decision from the European Commission is anticipated later this year.
Gilead Sciences has released Week 48 results from its pivotal Phase 3 trial assessing Hepcludex (bulevirtide) for chronic hepatitis delta virus (HDV). The data demonstrate significant viral declines and improved patient-reported outcomes (PROs). At Week 48, 45% and 48% of patients treated with bulevirtide achieved combined virological and biochemical responses, compared to only 2% in the untreated group. The treatment's safety profile remains consistent, with no serious adverse events. The findings were presented at the International Liver Congress 2022, reinforcing bulevirtide's potential as a therapeutic option for this high-burden disease.
Gilead Sciences (Nasdaq:GILD) announced over 80 abstracts will be presented at the International Liver Congress™ (ILC) 2022 from June 22-26, 2022. Key highlights include Phase 3 data on Hepcludex (bulevirtide) for treating hepatitis delta virus (HDV), focusing on efficacy and patient-reported outcomes. Presentations will also cover hepatitis C (HCV) elimination efforts, chronic hepatitis B (HBV) treatments, and research in nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Bulevirtide has received Conditional Marketing Authorization in Europe and is under FDA review in the U.S.
